“VERU-944 addresses a
“We had a very positive meeting with
Initially VERU-944 will be developed as a once weekly oral agent for the treatment of hot flashes that are often associated with the use of androgen deprivation therapy (ADT) in men with advanced prostate cancer. Approximately 80% of men receiving one of the common forms of ADT, including Lupron®, Eligard® and Firmagon®, experience hot flashes.
About Hot Flashes in Men with Prostate Cancer Undergoing Hormonal Therapy
More information about the Company and its products can be found at www.PREBOOST.com and www.fc2femalecondom.com. For corporate and investor-related information about the Company, please visit https://veruhealthcare.com/investors.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
Press Release Kari Sharp